The recent acquisition of UK-based BioFocus by the target identification and validation specialist Galapagos signals the latter's transformation into a relatively unusual kind of company: a fully integrated European biotech specialising in drug discovery. This feature explores some of the history of Galapagos, and the rationale behind the company's latest deal.